Viewing Study NCT00221754



Ignite Creation Date: 2024-05-05 @ 12:02 PM
Last Modification Date: 2024-10-26 @ 9:19 AM
Study NCT ID: NCT00221754
Status: COMPLETED
Last Update Posted: 2007-06-13
First Post: 2005-09-13

Brief Title: Pravastatin and Protease Inhibitors in HIV-Infected Patients
Sponsor: University Hospital Bordeaux
Organization: University Hospital Bordeaux

Study Overview

Official Title: Pravastatin in HIV-Infected Patients Treated With Highly Active Antiretroviral Therapy
Status: COMPLETED
Status Verified Date: 2007-06
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: To assess the use of pravastatin in hypercholesterolemic HIV-infected patients treated with protease inhibitors in a randomised double blind study
Detailed Description: Background Highly Active AntiRetroviral Therapy including protease inhibitors is associated with elevated plasma lipid levels

Design randomized double-blind multicentric

Intervention Pravastatin versus placebo for 12 weeks

Eligibility criteria Positive for anti-VIH antibodies stable antiretroviral therapy including at least one PI for 3 months plasma HIV-RNA level of 50 copiesmL for 3 months before randomization total cholesterol 55 mmolL with LDL-cholesterol 34 mmolL on fasting status after three months of standardized dietary advice written informed consent

Outcomes HIV RNA at 12 weeks

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
2001-026 None None None